Stocktoria
Longeveron Inc. LGVN
Longeveron Inc. (LGVN) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $1.2M at a -1893.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.6 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LGVN | Longeveron Inc. | 2/9 | — | — | — |
| SXTC | China SXT Pharmaceuticals, Inc. | 3/9 | 2.19 | — | — |
| VTGN | Vistagen Therapeutics, Inc. | 2/9 | — | — | — |
| IGC | IGC Pharma, Inc. | 3/9 | — | — | — |
| RNXT | RenovoRx, Inc. | 2/9 | — | — | — |
| DARE | Dare Bioscience, Inc. | 3/9 | — | — | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | 4/9 | — | — | — |
About Longeveron Inc.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
FAQ
Is LGVN financially healthy?
Longeveron Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does LGVN pay a dividend?
No, Longeveron Inc. does not currently pay a dividend.
How profitable is LGVN?
In FY2025, Longeveron Inc. had a net margin of -1893.6% and a return on equity of -400.1%.
What is the analyst price target for LGVN?
The average Wall-Street price target for Longeveron Inc. is $7.15, about 857.3% above the recent price, from 3 analysts.
Is LGVN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Longeveron Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.